Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats

Antiviral Research

Volumn 73, Issue 1, 2007, Pages 1-11

  Hammerbeck, David M ^a   Burleson, Gary R ^b   Schuller, Craig J ^b   Vasilakos, John P ^a   Tomai, Mark ^a   Egging, Elaine ^a   Cochran, Felicia R ^a   Woulfe, Susan ^a   Miller, Richard L ^a  

^a 3M COMPANY   (United States)

^b BRT Burleson Research Technologies Inc   (United States)

Author keywords

Cytokine; Influenza; Innate immunity; Interferon; Toll like receptor

Indexed keywords

3M 011; CPG 2059; CYTOKINE; GAMMA INTERFERON; IMIDAZOQUINOLINE DERIVATIVE; INTERFERON; INTERLEUKIN 12; N [2 (4 AMINO 2 ETHOXYMETHYL 1H IMIDAZO[4,5 C]QUINOLIN 1 YL) 1,1 DIMETHYLETHYL]METHANESULFONAMIDE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DRUG DOSE COMPARISON; FEMALE; HUMAN; HUMAN CELL; INFLUENZA; INFLUENZA VIRUS A H3N2; INTERFERON PRODUCTION; NONHUMAN; NOSE CAVITY; PRIORITY JOURNAL; RAT; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNITY, NATURAL; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; INTERFERON TYPE I; LEUKOCYTES, MONONUCLEAR; LUNG; RATS; RATS, INBRED F344; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8; VIRUS REPLICATION;

RATTUS; RNA VIRUSES;

EID: 33846181945     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.07.011     Document Type: Article

References (65)

1. Akira S., Uematsu S., and Takeuchi O. Pathogen recognition and innate immunity. Cell 124 (2006) 783-801
2. Arulanandam B.P., O'Toole M., and Metzger D.W. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J. Infect. Dis. 180 4 (1999) 940-949
3. Arulanandam B.P., Mittler J.N., Lee W.T., O'Toole M., and Metzger D.W. Neonatal administration of IL-12 enhances the protective efficacy of antiviral vaccines. J. Immunol. 164 7 (2000) 3698-3704
4. Bayley D., Temple C., Clay V., Steward A., and Lowther N. The transmucosal absorption of recombinant human interferon-alpha B/D hybrid in the rat and rabbit. J. Pharm. Pharmacol. 47 (1995) 721-724
5. Bernstein D.I., Harrison C.J., Tomai M.A., and Miller R.L. Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment. J. Infect. Dis. 183 (2001) 844-849
6. Bhardwaj N., Seder R.A., Reddy A., and Feldman M.V. IL-12 in conjunction with dendritic cells enhances antiviral CD8 + CTL responses in vitro. J. Clin. Invest. 98 3 (1996) 715-722
7. Brammer T.L., Murray E.L., Fukuda K., Hall H.E., Klimov A., and Cox N.J. Surveillance for influenza-United States, 1997-98, 1998-99, 1999-00 seasons. MMWR Surveill. Summ. 51 7 (2002) 1-10
8. Burleson G.R. Influenza virus host resistance model for assessment of immunotoxicity, immunostimulation, and antiviral compounds. In: Burleson G.R., Dean J.H., and Munson A.E. (Eds). Methods in Immunotoxicology vol. 2 (1995), Wiley-Liss, Inc., New York, NY 181-202 (Chapter 14)
9. Burleson G.R., and Burleson F.G. Bioassay of interferons. In: Burleson G.R., Dean J.H., and Munson A.E. (Eds). Methods in Immunotoxicology vol. 2 (1995), Wiley-Liss, Inc., New York, NY 345-356 (Chapter 20)
10. Burleson G.R., Ibanes J.D., and Morgan K.T. Immunology and immunotoxicity of the respiratory tract. Fund. Appl. Toxicol. 26 1 (1995) 11-19
11. Burleson G.R. Models of respiratory immunotoxicology and host resistance. Immunopharmacology 48 (2000) 315-318
12. Chen M., Griffith B.P., Lucia H.L., and Hsuing G.D. Efficacy of S26308 against guinea pig cytomegalovirus inoculation. Antimicrob. Agents Chemother. 32 (1988) 678-683
13. Choudhary S., Goa J., Leaman D.W., and De B.P. Interferon action against human parainfluenza virus type 3: involvement of a novel antiviral pathway in the inhibition of transcription. J. Virol. 75 10 (2001) 4823-4831
14. Clejan S., Mandrea E., Pandrea I.V., Dufour J., Japa S., and Veazey R.S. Immune responses induced by intranasal imiquimod and implications for therapeutics in rhinovirus infections. J. Cell. Mol. Med. 8 (2005) 457-461
15. Cluff C.W., Baldridge J.R., Stover A.G., Evans J.T., Johnson D.A., Lacy M.J., Clawson V.G., Yorgensen V.M., Johnson C.L., Livesay M.T., Hershberg R.M., and Persing D.H. Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. Infect. Immun. 73 5 (2005) 3044-3052
16. Cognasse F., Hamzeh H., Chavarin P., Acquart S., Genin C., and Garraud O. Evidence of Toll-like receptor molecules on human platelets. Immunol. Cell Biol. 83 (2005) 196-198
17. Diebold S.S., Kaisho T., Hemmi H., Akira S., Reis E., and Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303 5663 (2004) 1529-1531
18. Edwards K.M., Dupont W.D., Westrich M.K., Plummer W.D., Palmer P.S., and Wright P.F. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J. Infect. Dis. 169 (1994) 68-76
19. Ellis S.E., Coffey C.S., Mitchel Jr. E.F., Dittus R.S., and Griffin M.R. Influenza- and respiratory syntical virus-associated morbidity and mortality in the nursing home population. J. Am. Geriatr. Soc. 51 6 (2003) 761-767
20. Ferson M.J., Morton J.R., and Robertson P.W. Impact of influenza on morbidity in children with cystic fibrosis. J. Paediatr. Child Health 27 5 (1991) 308-311
21. Garcia-Sastre A. Mechanisms of inhibition of the host interferon alpha/beta-mediated antiviral responses by viruses. Microbes Infect. 4 6 (2002) 647-655
22. Gerster J.F., Lindstrom K.J., Miller R.L., Tomai M.A., Birmachu W., Bomersine S.N., Gibson S.J., Imbertson L.M., Jacobson J.R., Knafla R.T., Maye P.V., Nikolaides N., Oneyemi F.Y., Parkhurst G.J., Pecore S.E., Reiter M.J., Scribne L.S., Testerman T.L., Thompson N.J., Wagner T.L., Weeks C.E., Andre J.D., Lagain D., Bastard Y., and Lupu M. Synthesis and structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production. J. Med. Chem. 48 10 (2005) 3481-3491
23. Gibson S.J., Lindh J.M., Riter T.R., Gleason R.M., Rogers L.M., Fuller A.E., Oesterich J.L., Gorgen K.B., Qiu X., McKane S.W., Noelle R.J., Miller R.L., Kedl R., Fitgerald-Bocarsly P., Tomai M.A., and Vasilakos J.P. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR agonists, imiquimod and resiquimod. Cell Immunol. 218 (2002) 74-86
24. Gorden K.B., Gorski K.S., Gibson S.J., Kedl R.M., Kieper W.C., Qiu X., Tomai M., Alkan S.S., and Vasilakos J.P. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J. Immunol. 174 (2005) 1259-1268
25. Grandvaux N., tenOever B.R., Servant M.J., and Hiscott J. The interferon antiviral response: from viral invasion to evasion. Curr. Opin. Infect. Dis. 15 3 (2002) 259-267
26. Gupta A.K., Cherman A.M., and Tyring S.K. Viral and nonviral uses of imiquimod: a review. J. Cutan. Med. Surg. 8 (2004) 338-352
27. Gwaltney J.M. Combined antiviral and antimediator treatment of rhinovirus colds. J. Infect. Dis. 166 (1992) 776-782
28. Harper S.A., Fukuda K., Uyeki T.M., Cox N.J., and Bridges C.B. Prevention and control of influenza recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 54 RR-8 (2005) 1-40
29. Harrison C.J., Jenski L., Voychehovski T., and Bernstein D.I. Modification of immunological responses and clinical diseases during topical R-837 treatment of genital HSV-2 inoculation. Antivir. Res. 10 (1988) 209-224
30. Harrison C.J., Miller R.L., and Bernstein D.I. Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs. Antimicrob. Agents Chemother. 38 (1994) 2059-2064
31. Hayashi M., Satou E., Ueki R., Yano M., Miyano-Kurosaki N., Fujii M., and Takaku H. Resistance to influenza A virus inoculation by antigen-conjugated CpG oligonucleotides, a novel antigen-specific immunomodulator. Biochem. Biophys. Res. Commun. 329 1 (2005) 230-236
32. Hayden F.G., and Gwaltney Jr. J.M. Intranasal interferon-α2 treatment of experimental rhinoviral colds. J. Infect. Dis. 150 (1984) 174-180
33. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., Lipford G., Wagner H., and Bauer S. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303 5663 (2004) 1526-1529
34. Hemmi H., Kaisho T., Takeuchi O., Sato S., Sanjo H., Hoshino K., Horiuchi T., Tomizawa H., Takeda K., and Akira S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3 2 (2002) 196-200
35. Ibanes J.D., Morgan K.T., and Burleson G.R. Histopathological changes in the upper respiratory tract of F344 rats following infection with a rat adapted influenza virus. Vet. Pathol. 33 (1996) 412-418
36. Izurieta H.S., Thompson W.W., Kramarz P., Shay D.K., Davis R.L., DeStefano F., Black S., Shinefield H., and Fukuda K. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N. Engl. J. Med. 342 (2000) 232-239
37. Johnson A.G., Mohrman M., Odean M.J., Tomai M.A., and Miller R.L. Cellular and cytokine determinants of resistance to murine cytomegalovirus induced by imquimod and its analogues. Tenth International Symposium on Inoculations in the Immunocompromised Host. Davos, Switzerland (1998) (abstract)
38. Karupiah G., Xie Q.-W., Buller R.M.L., Nathan C., Duarte C., and MacMicking J.D. Inhibition of viral replication by interferon-gamma induced nitric oxide synthase. Science 261 (1993) 1445-1448
39. Karupiah G., Chen J.H., Mahalingam S., Nathan C.F., and MacMicking J.D. Rapid interferon gamma-dependent clearance of influenza A virus and protection from consolidating pneumonitis in nitric oxide synthase 2-deficient mice. J. Exp. Med. 188 8 (1998) 1541-1546
40. Kende M., Rill, Contos W.L., and Canonico M.J. Efficacy of a novel orally active immunomodulator S-26308 against arbovirus inoculations. Antivir. Res. 9 88 (1988) (abstract)
41. Lebrec H., and Burleson G.R. Influenza virus host resistance models in rats: utilization for immune function assessment and immunotoxicology. Toxicology 91 2 (1994) 179-188
42. Loutfy M.R., Blatt L.M., Siminovitch K.A., Ward S., Wolff B., Lho H., Pham D.H., Deif H., Lamere E.A., Chang M., Kain L.C., Farcas G.A., Ferguson P., Latchford M., Levy G., Dennis J.W., Lai E.K., and Fish E.N. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 290 (2003) 3222-3228
43. Lund J.M., Alexopoulou L., Sato A., Karow M., Adams N.C., Gale N.W., Iwasaki A., and Flavell R.A. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl. Acad. Sci. U.S.A. 101 15 (2004) 5598-5603
44. Matikainen S., Siren J., Tissari J., Veckman V., Pirhonen J., Severa M., Sun Q., Lin R., Meri S., Uze G., Hiscott J., and Julkunen I. Tumor necrosis factor alpha enhances influenza A virus-induced expression of antiviral cytokines by activating RIG-I gene expression. J. Virol. 80 7 (2006) 3515-3522
45. McCluskie M.J., and Davis H.L. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine 19 (2001) 413-422
46. Medzhitov R., and Janeway Jr. C. The Toll receptor family and microbial recognition. Trends Microbiol. 8 10 (2000) 452-456
47. Miller R.L., Imberson L.M., Reiter M.J., Schwartzmiller D.H., Pecore S.E., and Gerster J.F. Inhibition of herpes simplex virus infection in a guinea pig model by S-26308. Program and Abstracts of the 25th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Minneapolis, Minnesota (1985) (abstract)
48. Miller R.L., Gerster J.F., Owens M.L., Slade H.B., and Tomai M.A. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int. J. Immunopharmacol. 21 (1999) 1-14
49. Morrey J.D., Day C.W., Julander J.G., Blatt L.M., Smee D.R., and Sidwell R.W. Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models. Antivir. Chem. Chemother. 15 (2004) 101-109
50. Nicholson K.G., Ken T.J., and Ireland D.C. Respiratory viruses and exacerbations of asthma in adults. Br. Med. J. 307 6910 (1993) 982-986
51. Oh S., and Eichelberger M.C. Polarization of allogeneic T-cell responses by influenza virus-infected dendritic cells. Virology 74 17 (2000) 7738-7744
52. Okayama Y. Mast cell-derived cytokine expression induced via Fc receptors and Toll-like receptors. Chem. Immunol. Allergy 87 (2005) 101-110
53. Peng G., Guo Z., Kiniwa Y., Voo K.-S., Peng W., Fu T., Wang D.Y., Li Y., Wang H.Y., and Wang R.-F. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 309 (2005) 1380-1384
54. Pestka S., Krause C.D., and Walter M.R. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202 (2004) 8-32
55. Radsak M.P., Salih H.R., Rammensee H.G., and Schild H. Triggering receptor expressed on myeloid cells-1 in neutrophil inflammatory responses: differential regulation of activation and survival. J. Immunol. 172 8 (2004) 4956-4963
56. Rivest S. Molecular insights on the cerebral innate immune system. Brain Behav. Autoimmun. 17 (2003) 13-19
57. Seo S.H., and Webster R.G. Tumor necrosis factor alpha exerts powerful anti-influenza virus effects in lung epithelial cells. J. Virol. 76 3 (2002) 1071-1076
58. Stanley M.A. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin. Exp. Dermatol. 27 (2002) 571-577
59. Stokes J.R., Sorkness R.L., Kaplan M.R., Castleman W.L., Tomai M.A., Miller R.L., and Lemanske Jr. R.F. Attenuation of virus-induced airway dysfunction in rats treated with imiquimod. Eur. Respir. J. 11 2 (1998) 324-329
60. Takeda K., Kaisho T., and Akira S. Toll-like receptors. Annu. Rev. Immunol. 21 (2003) 335-376
61. Tan W.C., Xiang X., Qiu D., Ng T.P., Lam S.F., and Hegele R.G. Epidemiology of respiratory viruses in patients hospitalized with near-fatal asthma, acute exacerbations of asthma, or chronic obstructive pulmonary disease. Am. J. Med. 115 4 (2003) 272-277
62. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., and Fukuda K. Mortality associated with influenza and respiratory syntical virus in the United States. JAMA 289 2 (2003) 179-186
63. Wilde J.A., McMillan J.A., Serwint J., Butta J., O'Riordan M.A., and Steinhoff M.C. Effectiveness of influenza vaccine in health care professionals. JAMA 281 (1999) 908-913
64. Wong J.P., Nagata L.P., Christopher M.E., Salazar A.M., and Dale R.M. Prophylaxis of acute respiratory virus inoculations using nucleic acid-based drugs. Vaccine 23 17-18 (2005) 2266-2268
65. Yang X., Coriolan D., Maurthy V., Schultz K., Golenbock D.T., and Beasley D. Toll-like receptor 2 mediates persistent chemokine release by Chlamydia pneumoniae-infected vascular smooth muscle cells. Am. J. Physiol. Circ. Physiol. 289 (2005) H1069-H1076